Southwall Technologies, Inc. (OTCBB: SWTX), Majesco Entertainment Company (NASD: COOL), CardioVascular BioTherapeutics (OTCBB: CVBT), North-West Oil Group Inc. (OTC: NWOL)
Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://swtx.realpennies.com
SOUTHWALL TECHNOLOGIES (OTCBB: SWTX) "Up 18.64% in morning trading"
Southwall Technologies, Inc. develops, manufactures, and markets thin film coatings on flexible substrates for the automotive glass, electronic display, architectural glass, and window film markets. It develops various products that control sunlight in automotive glass, reduce light reflection, reduce electromagnetic radiation and improve image quality in electronic display products, and conserve energy via the application of architectural and after-market window film products. The company's products consist of transparent solar-control films for automotive glass; anti-reflective films for computer screens, including flat panel displays, plasma displays, and reflective films for back-lighting in liquid crystal displays; transparent conductive films for use in touch screen and plasma panel displays; energy control films for architectural glass; and various other coatings. It sells its products to original equipment manufacturers in North America, Europe, the Middle East, and Asia through direct sales force and sales representatives. The company was incorporated in 1979 and is headquartered in Palo Alto, California.
SWTX News:
December 7 - Southwall's Heat Mirror Insulating Glass Achieves Insulation Value of R-20/U-0.05 Equal to the Insulation of a Solid Wall
Southwall Technologies, Inc. (OTCBB: SWTX), the worldwide innovator of high performance, energy-saving films and glass products, announced that the ability of Heat Mirror insulating glass to insulate against heat loss at a record breaking R-20/U-0.05 insulation value.
R-20 Heat Mirror insulating glass consists of three heat reflective coated films mounted inside an insulating glass unit between two pieces of low-e coated glass. This super insulating glass construction creates four heat-impeding gas-filled cavities and achieves R-20 performance when used in conjunction with a thermally insulated fiberglass frame. Heat Mirror R-20 is a product of Alpen Energy Systems, a leading Southwall customer licensed to fabricate Heat Mirror insulating glass.
"This astounding achievement in energy efficiency is a tribute to the collaborative team effort of Southwall and its window and insulating glass customers who jointly push the envelope in enhancing the performance and value of Heat Mirror technology," said John Meade, Southwall's Director of Business Development
Superior to any low-e glass currently available, Heat Mirror is a technologically advanced low emissivity and solar reflective film that can be mounted inside an insulating glass unit in a variety of configurations (one, two or three coated films, uncoated or low-e coated glass) to provide energy conservation performance ranging from R-6 to R-20 to meet the unique requirements of commercial and residential new construction and renovation projects.
Heat Mirror is the technological alternative to coated glass that extends performance well beyond that of generic low-e glass available today. Heat Mirror insulating glass, as well as other innovative glass technologies currently under development, is driving the US Department of Energy to revise the glass performance standards of its Energy Star program that rates the energy efficiency of appliances and building components.
Scheduled to debut as early as 2009, revised Energy Star glass performance standards will make clear that generic low-e glass, with a maximum insulating performance level of R-4, no longer represents a level of energy efficiency required to "transform the market", a key charter of the agency's ratings and standards program. Among Energy Star's objectives is increased market penetration of windows achieving insulating performance of R-10 by 2010, an objective readily achieved by Heat Mirror technology today.
Why is increasing the energy efficiency of glass important? According to Chris Mathis, a founding member of the National Fenestration Rating Council (NFRC), which sets standards for window energy efficiency, 64 percent of the 110 million existing homes in the US have single-pane windows. This contributes 25%-35% of the total energy wasted in buildings and 10% of the total carbon emissions in the US annually.
Southwall Technologies, Inc. introduced the world's first low-e coated glass product in 1981, a pioneering technology recognized in 2000 by Popular Science magazine as one of the "Top 100 Inventions of the Millennium." Southwall's Heat Mirror insulating glass units are available from over 50 window and insulating glass manufacturers worldwide.
For more info: http://cool.realpennies.com
MAJESCO ENTERTAINMENT COMPANY (NASD: COOL) "Up 23.34% in morning trading"
Headquartered in Edison, NJ, with an international office based in Bristol, UK, Majesco Entertainment Company is an innovative provider of video games for the mass market, with a focus on publishing video games for leading portable systems and the Wii console. Product highlights include Nancy Drew, Cooking Mama 2: Dinner with Friends and Zoo Hospital for the Nintendo DS and Cooking Mama: Cook Off for the Wii console. More information about Majesco can be found online at www.majescoentertainment.com.
COOL News:
December 6 - Majesco Entertainment Names Jesse Sutton Chief Executive Officer
Majesco Entertainment Company (NASD: COOL), an innovative provider of video games for the mass market, appointed Jesse Sutton as its chief executive officer and Allan Grafman as its non-executive chairman of the board.
"As CEO, I will continue to guide Majesco into its next phase of growth by exploring new avenues in the digital entertainment market," said Jesse. "Most recently, we launched Majesco Studios, which enables us to leverage our technical and design expertise to specifically focus on products and titles targeting the casual gamer. We're excited about the opportunities that will result from this initiative and believe this move furthers our ability to build the same or better product as we do externally with similar or reduced costs. In addition, we are fortunate to announce that Allan Grafman has assumed the role of non-executive chairman of the board. His extensive knowledge of mass market entertainment franchises and the growing interactive media space will help guide the execution of the company's strategic goals."
"The board wants to thank Jesse for his strategic leadership and direction over the past 16 months," said Grafman. "In addition to driving the mass market strategy, Jesse has led expense reductions, financings and multiple new title releases. We are confident in his ability to aggressively build our business as he focuses on expanding the company's distribution channels and creating partnerships to increase sales."
Sutton, 38, has served as Majesco's interim CEO and a member of the board of directors since August 2006 and as president from 1996 to 2006. He has been involved in overseeing all aspects of the company's operations and has been a key architect of the company's mass market strategy.
Grafman, 54, has served as a member of Majesco's board of directors since April 2007. He is currently the President of All Media Ventures and has been an operating partner of Mercury Capital Partners since 2005. Previously, Grafman served as President of Archie Comics Entertainment and Executive Vice President, Chief Financial Officer of Hallmark Entertainment. From 1983 to 1996, at Tribune Entertainment he served as Vice President and at parent Tribune Company as Managing Director.
CARDIOVASCULAR BIOTHERAPEUTICS (OTCBB: CVBT) "Up 23.61% in morning trading"
For more info: http://cvbt.realpennies.com
CardioVascular BioTherapeutics, Inc., a development stage biopharmaceutical company, focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company uses an active pharmaceutical ingredient, the 141 amino acid form of fibroblast growth factor-1, in its drug candidates, which facilitates the growth of new blood vessels in the heart, and other tissues and organs with an impaired vascular system. Its products under development include CVBT-141A, a Phase I clinical trial completed product for use in the treatment of severe coronary heart disease; and CVBT-141B, which is in Phase I clinical trials for the treatment of diabetic, bedridden, and elderly patients suffering from wounds, open sores, and diabetic ulcers. The company also develops CVBT-141C, which has approval for Phase I clinical trials for the treatment of peripheral artery disease. In addition, CardioVascular BioTherapeutics' product portfolio includes CVBT-141D, which is under proof of concept clinical trials stage for the treatment of disc ischemia. Further, it develops CVBT-141E for the treatment of lumbar ischemia and CVBT-141H for the treatment of severe coronary heart disease?injection catheter delivery, which are under pre-clinical research and development stages. The company was founded in 1998 as CardioVascular Genetic Engineering, Inc. and changed its name to CardioVascular BioTherapeutics, Inc. in 2004. CardioVascular BioTherapeutics is headquartered in Las Vegas, Nevada.
CVBT News:
December 5 - Dutton Associates Announces Investment Opinion: CardioVascular BioTherapeutics Maintained at Speculative Buy Rating by Dutton Associates
Dutton Associates continues its coverage of CardioVascular BioTherapeutics (OTCBB: CVBT) maintaining a Speculative Buy rating and a $1.20 target price. The report by Dutton senior analyst Richard West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Knobias, Reuters, and other leading financial portals.
There have been several events announced since our research report of April 5, 2007, which impact the current and future investment status, centering on CardioVascular BioTherapeutics' (CardioVascular) progress of its drug candidates through the U.S. Food and Drug Administration (FDA) clinical trial process. In a November 28, 2007 Research Note, we reinstated our rating of Speculative Buy and assigned a 12-month price target of $1.20 per share for Cardio. Recently, CardioVascular announced the completion of its Phase I wound healing FDA clinical trial evaluating the safety and tolerability of its protein-based drug candidate CVBT-141B for dermal wound healing, formulated with human fibroblast growth factor -1 (FGF-1). CardioVascular is making positive progress with its ongoing FDA clinical trials for: severe coronary heart disease - surgical delivery and catheter, wound healing, and peripheral artery disease. In a recent question and answer session on a conference call, Cardio discussed the status of the $15.0 million PIPE that is currently on hold and reaffirmed that Cardio would not sell stock below $1.00 per share. Cardio also indicated that management and members of its board of directors are loaning the Company capital (at 6% interest) to allow the company to weather the current liquidity situation. Finally, they noted that the holder of a convertible note had completed its selling of the converted common stock that had been pressuring the stock down this past year.
NORTH-WEST OIL GROUP (OTC: NWOL) "Up 33.33% in morning trading"
For more info: http://nwol.realpennies.com
Formerly Nord Oil International, North-West Oil Group Inc. is a Russian public oil-producing and oil-distributing company. NWOG is a young, dynamically growing company that offers its services on the oil markets of Moscow, St. Petersburg and other industrial centers of Russia's European region. The company's activity lies in the sphere of oil and gas distribution, production and distribution of oil products and petrochemicals, construction of oil refineries.
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment